Latest News about BMRN
Recent news which mentions BMRN
BioMarin Valuation Fair, But Expectations From Hemophilia Therapy Too High, Says Analyst
January 30, 2023
Tickers
BMRN
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
January 30, 2023
From Benzinga
What 5 Analyst Ratings Have To Say About Biomarin Pharmaceutical
January 30, 2023
Tickers
BMRN
From Benzinga
3 Drug Stocks With Promising Pipelines for 2023
January 23, 2023
From InvestorPlace
Cramer Is Holding This Biotech Stock
January 12, 2023
From Benzinga
BioMarin's Growth Prospects Soar with Potential Voxzogo and Roctavian Launches, Analyst Raises Price Target
January 11, 2023
Tickers
BMRN
From Benzinga
6 Analysts Have This to Say About Biomarin Pharmaceutical
January 11, 2023
Tickers
BMRN
From Benzinga
2 Top Biotech Stocks Defying the Bear Market
January 10, 2023
From Motley Fool
Netflix, Workday, Costco, Caterpillar and more: These stocks are Cowen’s favorites for 2023
December 10, 2022
From MarketWatch
12 Health Care Stocks Moving In Thursday's Pre-Market Session
December 01, 2022
From Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
December 01, 2022
From Benzinga
From InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
November 29, 2022
From Benzinga
Canceled AdCom, UniQure's Hemgenix Approval Show Positive Signs For BioMarin's Hemophilia Candidate
November 23, 2022
Tickers
BMRN
From Benzinga
Why Biomarin Pharmaceutical Stock Hit A New 52-Week High Today
November 23, 2022
Tickers
BMRN
From Benzinga
$1.4 Million Bet On This Real Estate Stock? 3 Stocks Insiders Are Buying
November 03, 2022
From Benzinga
10 Analysts Have This to Say About Biomarin Pharmaceutical
October 31, 2022
Tickers
BMRN
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022
October 31, 2022
From Benzinga
Mastercard To $428? Plus This Analyst Slashes PT On Intel
October 31, 2022
From Benzinga
BioMarin Lays Off 4% Of Its Workforce To 'Simplify' The Company
October 07, 2022
Tickers
BMRN
From Benzinga
Do Back-to-Back Approvals Make This Biotech Stock a Buy Now?
September 22, 2022
From Motley Fool
BioMarin Says One Participant Diagnosed With Leukemia In Late-Stage Hemophilia Gene Therapy Trial
September 12, 2022
Tickers
BMRN
From Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
August 24, 2022
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.